Clinical Trials on Plaque Morphology in Russian Federation

Total 21 results

I.M. Sechenov First Moscow State Medical University

Recruiting

microRNAs in the Diagnosis of Atherosclerotic Plaque Instability

Atherosclerosis of Artery

Russian Federation
Samara Regional Cardiology Dispensary
Samara State Medical University

Recruiting

Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS (Combi-LLT ACS)

Dyslipidemias

Russian Federation
Biocad

Completed

An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis (BCD-085-7)

Moderate to Severe Plaque Psoriasis

Russian Federation
AbbVie (prior sponsor, Abbott)

Completed

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

Moderate to Severe Plaque Psoriasis

Russian Federation
Mabscale, LLC

Recruiting

Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®

Plaque Psoriasis

Russian Federation
Novartis Pharmaceuticals

Recruiting

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis (SPARROW)

Moderate-to-severe Plaque Psoriasis

Russian Federation
Alvotech Swiss AG

Completed

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Poland, Georgia, Iceland, Russian Federation, Ukraine
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE SURE)

Moderate to Severe Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
Fresenius Kabi SwissBioSim GmbH
Merck KGaA, Darmstadt, Germany

Completed

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis (AURIEL-PsO)

Psoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type Psoriasis

United States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
Mitsubishi Tanabe Pharma Corporation

Completed

Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Bulgaria, Russian Federation, Estonia, Hungary, Latvia, Poland, Ukraine, Germany
Novartis Pharmaceuticals

Completed

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

Belgium, Spain, Russian Federation, Germany, United States, Czechia, Peru, Poland, Estonia
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
Sandoz
Hexal AG

Completed

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel (EGALITY)

Chronic Stable Plaque Psoriasis

Germany, Romania, Bulgaria, Czech Republic, Estonia, Hungary, Poland, Russian Federation, Slovakia, South Africa, Ukraine, United Kingdom
UCB Biopharma SRL

Completed

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE READY)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, United Kingdom
Novartis Pharmaceuticals

Completed

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Chronic Severe Plaque-type Psoriasis

Belgium, Italy, Egypt, France, Hungary, Russian Federation, Germany, Israel, Spain, Japan, Estonia, United Kingdom, Poland, Colombia, United States, Latvia, Guatemala, Romania, Switzerland
Eli Lilly and Company

Completed

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis (Ixora-peds)

Plaque Psoriasis

United States, Spain, Puerto Rico, Czechia, Canada, Germany, France, Poland, Hungary, Mexico, Russian Federation, Argentina, Netherlands
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
Coherus Biosciences, Inc.

Completed

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PsOsim)

Plaque Psoriasis

United States, Canada, Bulgaria, Chile, Croatia, Estonia, Georgia, Israel, Italy, Latvia, Moldova, Republic of, Poland, Russian Federation, Slovakia, South Africa, Ukraine
Bausch Health Americas, Inc.

Terminated

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

Plaque Psoriasis

United States, Belgium, Italy, Hungary, Poland, Australia, France, Greece, Russian Federation, Latvia, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

United States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada
Novartis Pharmaceuticals

Completed

Plaque Psoriasis Efficacy and Safety With Secukinumab (OPTIMISE)

Plaque Psoriasis

Germany, Belgium, Spain, Croatia, Czechia, Greece, Hungary, Russian Federation, Netherlands, Austria, France, Switzerland, Israel, United Kingdom, Italy, Lithuania, Sweden, Bulgaria, Denmark, Finland, Portugal, Slovakia, Poland, Latvia

Clinical Trials on Plaque Morphology in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations